Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor.

Abstract: The present invention relates to novel formulations comprising a sprayable composition comprising tranexamic acid and chitosan for use in the treatment of wounds or injuries, in particular for use as a topical hemostatic composition or for surgical intervention and the process for preparation thereof.

Abstract: Compositions and methods for inducing pterygium regression from visual axis/central cornea, stabilizing pterygium, treating hyperemia and symptoms in pterygium patients, and treating pterygium recurrence following pterygiectomy are disclosed. The methods include administration of a multikinase inhibitor, an antimetabolite or a combination thereof to patients in need thereof.

Abstract: The present invention provides a nano-crystallized herbal ingredient-containing package for use in a food processor or being used directly to prepare a herbal decoction. The package includes a housing; single or multiple herbal ingredient nano-crystals; one or more non-additive and anti-caking spacers for preventing caking that blocks solvent flowing through the package towards the single or multiple herbal ingredient nano-crystals during processing by the food processor; and optionally one or more stabilizing agents for stabilizing the single or multiple herbal ingredient nano-crystals during nano-crystallization of the herbal ingredients and during preparation of the herbal decoction. A method of preparing a herbal decoction from the package is also provided.

Abstract: The invention relates to the preparation of a water soluble, powdered pharmaceutically active cannabinoid and/or terpene extract from plant materials, a powder where the bulk density can easily be modified depending on the final dosage form required. The extract is first treated with a solvent to solubilize the cannabinoids, then combined with an emulsifier. The solubilized mixture is then dried to evaporate the solvent, leaving the water-soluble cannabinoid extract powder. The resulting powder remaining stable at room temperature for at least one year and can be compounded into various pharmaceutical powdered formulations, with varying bulk powder densities.

Abstract: Described herein, inter alia, are peptide containing polymers, and methods of making and using the same.

Abstract: Provided are oil-in-water microemulsions for formulating pharmaceutically active compounds. The microemulsions contain oils, surfactants, water, and the pharmaceutical compounds, and are produced by mixing an aqueous phase and a lipid phase in which each phase contains at least one surfactant in a defined ratio whereby the resulting microemulsion has very small dispersed particles, and, is thermodynamically very stable.

Abstract: The present invention features compositions comprising a plurality of therapeutic agents wherein the presence of one therapeutic agent enhances the properties of at least one other therapeutic agent. In one embodiment, the therapeutic agents are cystic fibrosis transmembrane conductance regulators (CFTR) such as a CFTR corrector or CFTR potentiator for the treatment of CFTR mediated diseases such as cystic fibrosis. Methods and kits thereof are also disclosed.

Abstract: A composition which is used for the production of a solid preparation exhibiting a small variation of dissolution even at a low content of hydroxypropyl methyl cellulose (HPMC), and others. More specifically, provided are a composition for a solid preparation, the composition including HPMC having a polydispersity of 4.0 or more, as determined by absolute molecular weight measurement, and having a viscosity at 20° C. of 1,500 to 15,0000 mPa·s, as determined in a 2% by mass aqueous solution thereof, and an active ingredient; the solid preparation including the composition; and a method for producing a tablet including a step of dry-mixing said HPMC with an active ingredient to obtain a mixture, or granulating a mixture including said HPMC and an active ingredient to obtain a granulated product, and a step of tableting the mixture or the granulated product to obtain a tablet.

Abstract: There is provided a solid pharmaceutical composition for delivering by oral administration a pharmaceutically active binding polypeptide to a region of the intestinal tract comprising a compressed core, wherein the compressed core comprises a pharmaceutically active binding polypeptide and wherein the compressed core is coated with a pH sensitive enteric coating.

Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

Abstract: An ingestible pill is provided that includes an enteric coating and a medication-delivery device, which includes (a) a patch having upper and lower surfaces that face in generally opposite directions, and (b) needles. The patch is disposed within the enteric coating, folded so as to define one or more creases, which define respective inner and outer crease sides, wherein at least 50% of the needles are coupled to the patch along the inner crease sides. The patch is configured to assume, after the enteric coating dissolves, an expanded shape, in which the patch has an outer perimeter. Other embodiments are also described.

Abstract: The invention refers to a pharmaceutical or nutraceutical composition comprising a core a) comprising an active ingredient and a water-insoluble polymer, a coating layer b) above the core a) comprising a salt of an alginic acid, and a coating layer c) above the coating layer b) comprising an anionic (meth)acrylate copolymer polymerized from a (meth)acrylate monomer mixture comprising 5-75% by weight in relation to the total weight of the (meth)acrylate monomer mixture of (meth)acrylate monomers with an anionic group, wherein the amount of the water-insoluble polymer in the core a) is 2 to 20% by weight in relation to the weight of the core a) and the amount of the salt of an alginic acid in the coating layer b) is 5 to 85% by weight in relation to the weight of the core a) and the amount of the anionic (meth)acrylate copolymer in the coating layer c) is 10 to 75% by weight in relation to the weight of the core a) and to the coating layer b).

Abstract: The present disclosure relates to a method for manufacturing a device for herbal medicine in which the airborne release of medicinal ingredients can be controlled, which comprises: separating two or more medicinal herbal ingredients prescribed or prepared according to pharmacological effects on the basis of the weight ratio of each medicinal ingredient to total weight of the medicinal ingredients; grinding the medicinal ingredients separated on the basis of weight ratio, wherein fine particles are ground to different sizes according to the setting of release duration; preparing herbal medicine by mixing the ground medicinal ingredients together, and then mixing the ingredients with a binding agent; and adhering the herbal medicine to a base sheet.

Abstract: The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of asenapine comprising a self-adhesive layer structure containing a therapeutically effective amount of asenapine, such asenapine TTS for use in a method of treatment, processes of manufacture of such TTS as well as asenapine and transdermal therapeutic systems containing asenapine for use in a method of treatment and to a method of treating a human patient by transdermal administration of asenapine.

Abstract: The present disclosure provides compounds of the formula (I), (II), (III), wherein the variables are as defined herein for use in the treatment of fungal infections. In some embodiments, the fungal infection is an infection of Cryptococcus neojormans fungus. Also provided herein are compositions comprising a compound of formula I, II, or III and a second anti-fungal agent.

Abstract: Disclosed herein are compositions and methods for modulating the liver receptor homolog-1.

Abstract: This disclosure features compounds and compositions that are useful in methods of treating coronavirus infections (e.g., useful in methods of treating COVID-19) in a subject in need thereof. The methods include administering to the subject niclosamide compounds (or pharmaceutically acceptable salts and/or co-crystals thereof, e.g., niclosamide). In some embodiments, the niclosamide compounds have one or more properties that include, but are not limited to: a particular purity (e.g., a chemical purity of greater than about 99.0%) or a particular particle size (e.g., a particular particle size distribution and/or a particular particle size range and/or a specific surface area range). In an aspect, the niclosamide compounds described herein (e.g., niclosamide) can form part of compositions, dosage forms (e.g., unit dosage forms), and the like, which are suitable for respiratory administration (e.g., via inhalation and/or intranasally). In another aspect, the niclosamide compounds described herein (e.g.

Abstract: Ready-to-use, stable aqueous intravenous tranexamic acid compositions are provided.

Abstract: Compositions of L-4-chlorokynurenic are provided, as are methods for the treatment of neurological dysfunction.

Abstract: Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.

Abstract: Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.

Abstract: Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.

Abstract: The present invention provides wound healing compounds, compositions thereof, and methods of treatment using the same.

Abstract: Provided herein is technology relating to lipid compositions containing bioactive fatty acids and particularly, but not exclusively, to compositions and methods related to the production and use of structured lipid compositions containing sciadonic and/or pinoleic acid alone or in combination with other bioactive fatty acids including, but not limited to, eicosapentaenoic acid, docosahexaenoic acid, conjugated linoleic acid, and non-?-oxidizable fatty acid analogues such as tetradecylthioacetic acid.

Abstract: Methods of treating anxiety disorders or reducing anxiety-related behaviors. The methods include administering a therapeutically effective amount of ketone supplementation, such as butanediol, ketone esters (e.g., 1,3-butanediol-acetoacetate diester) and/or ketone salts (e.g., beta-hydroxybutyrate-mineral salt), chronically, sub-chronically, or acutely, with or without admixture with a medium chain triglyceride or in combination. It was determined herein that ketone supplementation reduced anxiety in rats on elevated plus maze as measured by less entries to closed arms, more time spent in open arms, more distance travelled in open arms, and delayed latency to entrance to closed arms, when compared to control. Along with reducing anxiety-related behavior, the chronic, sub-chronic, and acute ketone supplements also caused significant elevation of blood ?HB levels and changed blood glucose levels.

Abstract: Products and methods for treating cancer in a human patient comprising administering to the patient therapeutically effective amount of a first pharmaceutically active agent, wherein the first pharmaceutically active agent is one of an isothiocyanatostilbene and a pharmacologically acceptable salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analog thereof, or a combination thereof.

Abstract: The invention provides use of entacapone, an entacapone derivative or a stereoisomer, hydride, or pharmaceutically-acceptable salt thereof, in a person in need thereof, to treat or inhibit macular degeneration or age-related macular degeneration, and related compostions.

Abstract: Provided are compounds and methods for treating neurodegenerative diseases and conditions, such as multiple sclerosis, using an estrogen receptor-? ligand (ER? ligand).

Abstract: This invention discloses pharmaceutical use of a dicycloplatin (DCP) for the prophylaxis or treatment of leukemia, renal adenocarcinoma or melanoma. Methods using DCP, either alone or in combination with at least one additional therapeutic agent or adjuvant therapy agent, are also disclosed.

Abstract: The present invention relates to tiglien-3-one compounds and their use in methods of treating or preventing protozoal infections, bacterial infections, parasitic infections and cell proliferative disorders.

Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

Abstract: A protein crosslinker delivery device includes a body and a protein crosslinker held in a synthetic or natural biodegradable polymer. The body, a coating on the body, or an attachment to the body can contain the protein crosslinker holding biodegradable polymer. The release rate of the crosslinker and total amount of crosslinker released can be controlled by varying the concentration of the crosslinker and by varying the composition and structural characteristics of the degradable polymer. Surface eroding, bulk eroding and naturally occurring biodegradable polymers can be used in conjunction with a variety of nontoxic or minimally-toxic protein crosslinking agents. The devices can be used to treat mechanically damaged, deformed, and nutritionally deficient connective or soft tissues such as the knee meniscus, the spinal disc, the cornea, ligaments and tendons, the soft palate, and skin.

Abstract: Disclosed herein are “ketannabis” (or “ketonnabis”) compositions including a combination of: (1) tetrahydrocannabinol (THC); (2) a ketone body component such as beta-hydroxybutyrate (BHB) and/or acetoacetate; and (3) a dietetically or pharmaceutically acceptable carrier. Also disclosed herein are methods of using such ketannabis compositions for producing desired physiological effects. The ketannabis compositions beneficially enhance the euphoric effects of THC without aggravating common side effects or even acting to reduce common side effects such as anxiety, disruption of short-term memory, appetite increases, heart rate increases, and blood pressure changes.

Abstract: Apparatuses, methods, and systems for extraction, isolation, purification, and conversion of various cannabinoids, and modifications of whole-plant hemp extracts therewith are presented. A method for preparing a whole-plant hemp extract based product includes extracting cannabinoids from plant materials, such as one or more hemp varieties of Cannabis sativa. The method also includes separating and purifying CBD from the extracted cannabinoids, converting purified CBD to ?9-THC and ?8-THC and concurrently converting ?9-THC to CBN, purifying and separating the CBN, and combining the purified CBN with a whole-plan hemp extract. Products and supplements related to the method are also described.

Abstract: Provided herein are methods of treating and sensitizing cancer comprising administering a glycolytic inhibitor and an oxidative phosphorylation inhibitor.

Abstract: The present invention relates to a pharmaceutical composition or medical device comprising a fucoidan and at least one compound of formula A or B: wherein R1 and R2 are independently selected from the group consisting of —OH, —CH3, —CF3CH2O—, and CH3O—. Such pharmaceutical composition or medical device is notably useful for the treatment and/or prevention of a skin disorder involving excessive angiogenesis and/or fibrogenesis, such as in skin fibrosis, angiofibromas, hamartomas and periungual fibromas, skin manifestation occurring with rosacea, acne, atopic dermatitis, scleroderma, psoriasis and lupus erythematosus, and especially of Tuberous Sclerosis Complex and skin manifestation occurring with Tuberous Sclerosis Complex.

Abstract: The present invention relates to a pharmaceutical combination for use in the treatment of squamous cell carcinoma, comprising a CDK inhibitor selected from the compounds of formula (I); or a pharmaceutically acceptable salt thereof and one or more antineoplastic agents selected from sorafenib, lapatinib, erlotinib, cisplatin, 5-fluorouracil, docetaxel or cetuximab or a pharmaceutically acceptable salt thereof. The said pharmaceutical combination exhibits synergy when used in the treatment of squamous cell carcinoma of head and neck (SCCHN). The invention also relates to a pharmaceutical composition comprising the said combination and a method for the treatment of squamous cell carcinoma of head and neck (SCCHN), using a therapeutically effective amount of said combination.

Abstract: The present application relates to compounds of formula (I), wherein A, R, R1, and R2 are as defined in the specification, pharmaceutical compositions containing such compounds and to their use in therapy.

Abstract: The invention features methods for inhibiting the formation, reducing the size, and slowing the growth of an osteochondroma in a subject with multiple osteochondroma (MO) by administering to the subject palovarotene (also known as R667), or a pharmaceutically acceptable salt thereof. The methods described herein can also ameliorate complications associated with osteochondroma formation and growth in a subject with MO.

Abstract: The present invention relates to methods and pharmaceutical compositions useful for the treatment of hyperglycemia. Thorough multiple analyses, inventors demonstrated that Gfi1 is expressed in pancreatic acinar cells, starting from the first stages of pancreatic embryonic development. Furthermore, they observed that Gfi1 mRNA levels remain steady throughout embryonic development, while they significantly increase during the first days of life. They challenged conditional mutant mice with high fat diet for 5 months and monitored their weight and glycemia weekly. All the animals displayed a rapid increase in body mass as expected. While control mice rapidly developed a massive hyperglycemia, mutant mice remained normoglycemic throughout the entire experiment. A similar protection from induced diabetes was observed upon treatment with a high dose of Streptozotocin.

Abstract: The present invention discloses compositions, means and kits thereof for treating neuronal clinical indications in a mammalian subject. The composition comprises, inter alia, a synergistic combination of an anti-inflammatory drug and a DICER activator. The present invention further discloses methods for treating neuronal diseases including Motor neuron diseases (MNDs), ALS, FTD (Frontotemporal Dementia), macular degeneration (AMD) autism, and neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease.

Abstract: The present invention generally relates to 6-amino-2,4-dihydropyrano [2,3-c] pyrazoles as a ubiquitin specific protease 7(USP7) inhibitor useful for the treatment of diseases mediated by malfunction of USP7, such as inflammation, cancer, and immunological disorders. The invention described herein also pertains to pharmaceutical compositions and methods for treating diseases mediated by malfunction of USP7, in mammals using compounds disclosed herein.

Abstract: The present application discloses a pharmaceutical preparation comprising a de-epoxidized epothilone derivative, and especially relates to a preparation formulation of a compound with reduced allergens and toxicity; and also relates to the use thereof in the treatment of tumours, especially the use thereof in the treatment of solid tumours that are resistant to and fail to respond to other conventional chemotherapeutic agents, as well as the use thereof in the treatment of cancers alone or in combination with other tumour drugs or auxiliary drugs.

Abstract: Disclosed herein are methods of treating diseases associated with increased numbers of eosinophils basophils, and/or neutrophils with R(+) pramipexole.

Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.

Abstract: The current invention is in the field of molecular biology/pharmacology and provides methods of using compounds that modulate the effects of GPR30/GPER for treating obesity and diabetes (preferably agonists) as well as disease states and/or conditions that result from excessive formation of reactive oxygen species (preferably antagonists). These compounds may function as agonists and/or antagonists of the disclosed estrogen receptor and/or modulate the expression/upregulation of nox and nox-associated reactive oxygen species (ROS).

Abstract: The present invention generally relates to the early prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in infants or children. For example, the present invention relates to the prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in infants or children through appropriate nutrition for women desiring to get pregnant and/or during pregnancy and/or lactation. Embodiments of the present invention relate to the Vitamin B6 for use in the prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in the offspring, wherein the vitamin B6 is administered to women desiring to get pregnant and/or to the mother during pregnancy and/or lactation and to maternal food compositions that can be used for this purpose.

Abstract: Provided is a drug or method for treating or preventing a condition, disorder, or disease of the corneal endothelium caused by transforming growth factor-? (TGF-?) signals, mitochondrial abnormalities, and/or endoplasmic reticulum (ER) associated stress in corneal endothelial cells, using p38 MAP kinase inhibitors. The present invention provides a drug which includes p38 MAP kinase inhibitors, and which is for treating or preventing a condition, disorder, or disease of the corneal endothelium caused by TGF-? signals and/or mitochondrial abnormalities in corneal endothelial cells. In the preferred embodiment, the condition, disorder, or disease of the corneal endothelium is Fuchs' corneal endothelial dystrophy.

Abstract: Provided are methods and compositions for treating cancers in patients carrying an IDH1 mutation using an inhibitor of a mutant IDH1 enzyme.